Lupin Looks to Buy Inhaler Brand from Sanofi's Zentiva

Mar 06, 2017

moneycontrol.com

India-based Lupin is holding discussions with Sanofi’s generic arm, Zentiva, to acquire Pulmojet, its dry powder inhalation brand, according to CNBC TV18 sources.

Lupin hopes the deal will boost its global inhalation therapy business, as it looks to grow in the U.S. market. Lupin says it is developing nine compounds in the inhalation segment.

In recent news for Lupin, the drugmaker has received U.S. FDa approval to market a generic version of Braintree Laboratories’s Suprep Bowel Prep Kit and launched scalp treatment and a dermatology drug in the U.S. The company has also entered into a marketing agreement in Japan to exclusively distribute and promote extended-release tablets of schizophrenia drug.

Read the moneycontrol article

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments